YKL-40 and matrix metalloproteinases as potential biomarkers of inflammation and fibrosis in the development of bronchiolitis obliterans syndrome

Main Article Content

E.A. Kastelijn
C.H.M. van Moorsel
H.J.T. Ruven
N.M. Korthagen
J.M. Kwakkel-van Erp
E.A. van de Graaf
P. Zanen
D.A. van Kessel
J.C Grutters

Keywords

Bronchiolitis oblyterans syndrome, lung transplantation, matrix metalloproteinases

Abstract

Background and objective: The development of bronchiolitis obliterans syndrome (BOS) after lung transplantation is characterized by inflammation, remodeling and fibrosis. Both YKL-40 and matrix metalloproteinase (MMP)-9 have shown to be involved in these processes.We measured serial YKL-40 and MMP-9 serum levels in lung transplant recipients and assessed their usefulness as biomarker for BOS. Furthermore, we investigate the relationship between these two potential biomarkers of BOS and MMP-7. Design: Ten patients with BOS (BOSpos) and 10 matched patients without BOS (BOSneg) were included. Serial serum samples were collected after lung transplantation and prior to BOS. YKL-40, MMP-9 and MMP-7 serum levels were determined by ELISA. Results: The median concentrations of YKL-40 did not differ between BOSpos and BOSneg patients (p > 0.05). The median concentration of MMP-9 in BOSpos patients was significantly higher than in BOSneg patients (p < 0.0001). For MMP-9 as possible risk factor for BOS, a cut off value of 145 ng/ml has a sensitivity of 90% and a negative predictive value of 83%. Longitudinal analysis of YKL-40 andMMP-9 serum levels from the early post-transplant period onwards did not reveal a significant trend in time in both serum levels preceding BOS. In BOSneg patients MMP-9 showed an inverse relationship with MMP-7, that was absent in BOSpos patients. Conclusions: From the moment of transplantation onwards, patients who eventually developed BOS had significantly increased MMP-9 serum levels in comparison with patients who did not develop BOS. Therefore, increased MMP-9 serum levels might be useful as risk factor for BOS.

Abstract 66 | PDF Downloads 50